Views & Analysis Overcoming the challenges of developing vaccines in an accel... The COVID-19 pandemic stopped the world in its tracks.
Views & Analysis Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results... Last month, pharmaphorum spoke with Dr Charles C.
Views & Analysis Propelling clinical research into the 21st century Two and a half years ago, Covid-19 began to infect hundreds, then thousands, then millions of people, and was eventually declared a global pandemic.
Views & Analysis Capturing progress in haemophilia care If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today.
Views & Analysis Pandemic boost to decentralised trials is here to stay Due to the pandemic, decentralised trial solutions made the shift from an emerging trend to a crucial element of drug development.
Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
